Stem Cell Market Synopsis:
Stem Cell Market Size Was Valued at USD 12.94 Billion in 2023 and is Projected to Reach USD 24.60 Billion by 2032, Growing at a CAGR of 7.4% From 2024-2032.
Stem cells are cells with the ability to develop into many different types of cells in the body. They provide a repair system for the body. There are two main types of stem cells, adult stem cells and embryonic stem cells. Stem cells are found in almost all tissues of the body. They are needed for the maintenance of tissue and also for repair after injury.
The stem cell market is influenced by various applications such as HSC transplantation, HSC therapy (HSTC), Placental stem cell therapy, Autologous limbal stem cells (holoclar) transplantation, Development toward artificial organ engineering, Anti-aging effects, Treatment of diabetes, and many more which influence the demand of stem cells in the healthcare sector.
The future of stem cell research holds great promise, it is imperative to overcome the challenges and ethical considerations that come with such groundbreaking advancements which include stem cells in gene editing by combining stem cell technology with gene editing methods like CRISPR-Cas9, new opportunities for treating hereditary disorders and fixing genetic flaws are made possible.
For instance, in February 2024, the World Health Organization determined in a recent survey that there will be a 77% increase in the risk of developing cancer by 2050. Additionally, stem cells play an important role in regenerative medicine, aiding in tissue repair and organ regeneration. Investments in biotechnology and pharmaceuticals are further fueling this growth. As stem cell research advances, it is poised to revolutionize cancer treatment and improve patient outcomes globally. The expanding stem cell market offers hope for addressing the growing cancer burden and other serious diseases.
Stem Cell Market Trend Analysis:
Increasing Popularity as a Form of Regenerative Medicine
- Significant advancements in clinical applications and essential research of stem cells in regenerative medicine and other domains have occurred in recent years, motivating individuals to examine deeper into the study of stem cells. Stem cells, owing to their limitless capacity for self-renewal, offer vast potential for upgrading in the treatment of various diseases and human organ damage.
- Introducing CRISPR-Cas9 gene-editing technology in stem cell research has created new opportunities. Scientists’ precise manipulation of stem cell genetic material has emerged as a viable approach for changing genetic mutations that underlie a wide range of inherited disorders?
- For instance, in September 2023, SKAN Research Trust (SKAN) collaborated with the Wellcome-MRC Cambridge Stem Cell Institute (CSCI) based in the UK. The partnership includes a joint research initiative focused on investigating the genomic patterns associated with age-related neurodegenerative diseases within an Indian cohort.
The Transformative Potential of Interdisciplinary Approaches in Addressing Healthcare Needs
- Regardless of rigorous testing in cell lines and preclinical models of disease 90 percent of drug attrition is reported after entering human clinical trials. Such high failure rates amount to huge losses in time and cost to the healthcare and pharma industry. Due to such astronomical failure rates in drug discovery programs across the globe for several human diseases, healthcare research has undergone a paradigm shift owing to recent cutting-edge research endeavors in stem cells and regenerative medicine.
- Stem cell-based derivates integrated with genome and bioengineering approaches are emerging as the new age Advanced Therapy Medicinal products opening ground-breaking opportunities for the treatment of degenerative diseases and injury. Thus, there is an immense need for personnel with the know-how and skill sets in stem cell culture and stem cell-based product development for clinical usage. Consequently, the use of stem cells in creating cutting-edge therapeutics is likely to significantly boost the market growth.
Stem Cell Market Segment Analysis:
The Stem Cell Market is Segmented on the basis of product type, technology, application, treatment type, end-user, and region.
By Product Type, the Adult Stem Cell segment is expected to dominate the market during the forecast period
- Adult stem cells stand out in the domain of regenerative biology due to their distinctive characteristics and key roles in maintaining tissue homeostasis33. Multipotency is the ability of cells to possess various potential fates or abilities to develop into a restricted, diverse array of cellular phenotypes. ASCs are an appealing therapeutic choice for degenerative diseases. Due to their functions in tissue repair and regeneration, they are desirable targets for therapies aimed at slowing the advancement of illnesses marked by cellular degeneration These applications in the pharmaceutical and biotechnology sectors are the key drivers in the market.
- For instance, in October 2024, A cross-disciplinary team, led by the University of Glasgow, alongside the Universities of Nottingham and Strathclyde, used pioneering technology to manufacture human stem cells outside the body, with the hope that these cells could help tissue regeneration to repair broken bones, assist with transplant therapies, and aid in the development of new approaches to blood cancer treatment. The new project was made possible with USD 13.5 Million, awarded by the UKRI Engineering and Physical Sciences Research Council (EPSRC), as part of the funding for five new research hubs aimed at tackling some of the biggest problems in healthcare and society with ground-breaking new technologies and approaches. This project has the potential to accelerate the commercialization and clinical application of stem cells, expanding the market and offering new therapies for patients.
By Technology, the Cell Acquisition segment held the largest share in 2023
- The use of iPSCs (cells that are reprogrammed from adult cells to an embryonic-like state) for disease modeling is based on the fact that these cells are capable of self-renewing and that these cells can differentiate into all types of cells of the human body which can be utilized for the preparation of different disease models to study those diseases. Moreover, a patient-specific iPSC could be of enormous use as far as the development of a specific therapeutics’ regimen/drug is concerned.
- iPSCs have the potential of providing native cells for splicing and post-translational modifications that do not come with the small molecule screening systems using purified protein or recombinant cell lines used for the over-expression of the protein of interest which has aided in the process of drug screening. The use of iPSCs in drug screening has also been reported. Stem Cells enable the identification of molecules therapeutically useful and able to modulate the behavior of tumorigenic and normal stem cells. However, as the use of ESC is limited due to the concerned ethical issues, iPSCs (normal and tumorigenic) can be used as an alternative. Consequently, research and development in the healthcare sector are responsible for propelling the cell acquisition segment in the forecast period.
Stem Cell Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast Period
- The presence of innovators and key market players has resulted in the extended invasion of market products in the region. North America leads the market owing to the robust biotechnology industry, the presence of key players, extensive R&D, and the promotion of personalized medicines. The region accounts for the highest revenue share. Moreover, growth in this region can be further attributed to rising government initiatives for promoting stem cell therapies.
- For instance, in April 2023, The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy that was designed to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product was intended for use in adults and pediatric patients 12 years and older with blood cancers who were planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). In summary, the approval of Omisirge provides a promising new therapeutic option for blood cancer patients, with the potential to enhance patient outcomes, lower the risk of infections, and contribute to the overall growth and expansion of the stem cell market.
Active Key Players in the Stem Cell Market:
- AlloVir (USA)
- Aspen Neuroscience (USA)
- Astellas Pharma (Japan)
- Bluebird Bio (USA)
- Celgene (Bristol-Myers Squibb) (USA)
- Cynata Therapeutics (Australia)
- Fate Therapeutics (USA)
- International Stem Cell Corporation (USA)
- Kite Pharma (Gilead Sciences) (USA)
- Lonza Group (Switzerland)
- Mesoblast Limited (Australia)
- Novartis (Switzerland)
- NuVasive (USA)
- Organovo (USA)
- Regeneron Pharmaceuticals (USA)
- Regenexx (USA)
- Sangamo Therapeutics (USA)
- Stemcell Technologies (Canada)
- Stemline Therapeutics (Astellas Pharma) (USA)
- Thermo Fisher Scientific (USA)
- Tigenix (Takeda Pharmaceutical) (Belgium)
- Other Active Players
Key Industry Developments in the Stem Cell Market:
- In November 2024, Speeding up Stem Cell Research Genome BC, STEMCELL Technologies, and UBC have Partnered to Accelerate the Ability to Develop Stem Cells. This initiative aims to accelerate the generation of specific cell types from stem cells, potentially advancing new disease treatments.
- In July 2024, STEMCELL Technologies commercially launched the CellPore Transfection System, providing a groundbreaking new technology with the potential to advance cell engineering research and the development of novel cell therapies to cure diseases.
- In July 2024, The Government of Canada invested in a robust, dynamic, and resilient life sciences ecosystem capable of responding to current and future health emergencies. Since March 2020, over $2.2 billion has been invested to strengthen the country’s domestic biomanufacturing and life sciences capabilities to ensure Canadians have access to the most cutting-edge medical technologies.
- In February 2024, STEMCELL Technologies announced the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation).
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Stem Cell Market by Product Type
4.1 Stem Cell Market Snapshot and Growth Engine
4.2 Stem Cell Market Overview
4.3 Adult Stem Cells (ASCs)
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Adult Stem Cells (ASCs): Geographic Segmentation Analysis
4.4 Human Embryonic Stem Cells (HESCs)
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Human Embryonic Stem Cells (HESCs): Geographic Segmentation Analysis
4.5 Induced Pluripotent Stem Cells (iPSCs)
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Induced Pluripotent Stem Cells (iPSCs): Geographic Segmentation Analysis
4.6 Very Small Embryonic Like Stem Cells
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Very Small Embryonic Like Stem Cells: Geographic Segmentation Analysis
Chapter 5: Stem Cell Market by Technology
5.1 Stem Cell Market Snapshot and Growth Engine
5.2 Stem Cell Market Overview
5.3 Cell Acquisition
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Cell Acquisition: Geographic Segmentation Analysis
5.4 Cell Production
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Cell Production: Geographic Segmentation Analysis
5.5 Cryopreservation
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Cryopreservation: Geographic Segmentation Analysis
5.6 Expansion & Sub-Culture
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Expansion & Sub-Culture: Geographic Segmentation Analysis
Chapter 6: Stem Cell Market by Treatment Type
6.1 Stem Cell Market Snapshot and Growth Engine
6.2 Stem Cell Market Overview
6.3 Allogeneic Stem Cell Therapy
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Allogeneic Stem Cell Therapy: Geographic Segmentation Analysis
6.4 Auto Logic Stem Cell Therapy
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Auto Logic Stem Cell Therapy: Geographic Segmentation Analysis
6.5 Syngeneic Stem Cell Therapy
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Syngeneic Stem Cell Therapy: Geographic Segmentation Analysis
Chapter 7: Stem Cell Market by Application
7.1 Stem Cell Market Snapshot and Growth Engine
7.2 Stem Cell Market Overview
7.3 Neurological Disorders
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 Neurological Disorders: Geographic Segmentation Analysis
7.4 Orthopedic Treatments
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Orthopedic Treatments: Geographic Segmentation Analysis
7.5 Oncology Disorders
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Oncology Disorders: Geographic Segmentation Analysis
7.6 Injuries & Wounds
7.6.1 Introduction and Market Overview
7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.6.3 Key Market Trends, Growth Factors and Opportunities
7.6.4 Injuries & Wounds: Geographic Segmentation Analysis
7.7 Drug Discovery & Development
7.7.1 Introduction and Market Overview
7.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.7.3 Key Market Trends, Growth Factors and Opportunities
7.7.4 Drug Discovery & Development: Geographic Segmentation Analysis
7.8 and Other
7.8.1 Introduction and Market Overview
7.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.8.3 Key Market Trends, Growth Factors and Opportunities
7.8.4 and Other: Geographic Segmentation Analysis
Chapter 8: Stem Cell Market by End-User
8.1 Stem Cell Market Snapshot and Growth Engine
8.2 Stem Cell Market Overview
8.3 Pharmaceutical and Biotechnology Companies
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.3.3 Key Market Trends, Growth Factors and Opportunities
8.3.4 Pharmaceutical and Biotechnology Companies: Geographic Segmentation Analysis
8.4 Hospitals & Cell Banks
8.4.1 Introduction and Market Overview
8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.4.3 Key Market Trends, Growth Factors and Opportunities
8.4.4 Hospitals & Cell Banks: Geographic Segmentation Analysis
8.5 Academic & Research Institutes
8.5.1 Introduction and Market Overview
8.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
8.5.3 Key Market Trends, Growth Factors and Opportunities
8.5.4 Academic & Research Institutes: Geographic Segmentation Analysis
Chapter 9: Company Profiles and Competitive Analysis
9.1 Competitive Landscape
9.1.1 Competitive Benchmarking
9.1.2 Stem Cell Market Share by Manufacturer (2023)
9.1.3 Industry BCG Matrix
9.1.4 Heat Map Analysis
9.1.5 Mergers and Acquisitions
9.2 ASPEN NEUROSCIENCE (USA)
9.2.1 Company Overview
9.2.2 Key Executives
9.2.3 Company Snapshot
9.2.4 Role of the Company in the Market
9.2.5 Sustainability and Social Responsibility
9.2.6 Operating Business Segments
9.2.7 Product Portfolio
9.2.8 Business Performance
9.2.9 Key Strategic Moves and Recent Developments
9.2.10 SWOT Analysis
9.3 THERMO FISHER SCIENTIFIC (USA)
9.4 KITE PHARMA (GILEAD SCIENCES) (USA)
9.5 STEMCELL TECHNOLOGIES (CANADA)
9.6 LONZA GROUP (SWITZERLAND)
9.7 BLUEBIRD BIO (USA)
9.8 ORGANOVO (USA)
9.9 ASTELLAS PHARMA (JAPAN)
9.10 CYNATA THERAPEUTICS (AUSTRALIA)
9.11 CELGENE (BRISTOL-MYERS SQUIBB) (USA)
9.12 NOVARTIS (SWITZERLAND)
9.13 REGENERON PHARMACEUTICALS (USA)
9.14 SANGAMO THERAPEUTICS (USA)
9.15 REGENEXX (USA)
9.16 STEMLINE THERAPEUTICS (ASTELLAS PHARMA) (USA)
9.17 TIGENIX (TAKEDA PHARMACEUTICAL) (BELGIUM)
9.18 NUVASIVE (USA)
9.19 INTERNATIONAL STEM CELL CORPORATION (USA)
9.20 ALLOVIR (USA)
9.21 FATE THERAPEUTICS (USA)
9.22 MESOBLAST LIMITED (AUSTRALIA)
9.23 OTHER ACTIVE PLAYERS.
Chapter 10: Global Stem Cell Market By Region
10.1 Overview
10.2 . North America Stem Cell Market
10.2.1 Key Market Trends, Growth Factors and Opportunities
10.2.2 Top Key Companies
10.2.3 Historic and Forecasted Market Size by Segments
10.2.4 Historic and Forecasted Market Size By Product Type
10.2.4.1 Adult Stem Cells (ASCs)
10.2.4.2 Human Embryonic Stem Cells (HESCs)
10.2.4.3 Induced Pluripotent Stem Cells (iPSCs)
10.2.4.4 Very Small Embryonic Like Stem Cells
10.2.5 Historic and Forecasted Market Size By Technology
10.2.5.1 Cell Acquisition
10.2.5.2 Cell Production
10.2.5.3 Cryopreservation
10.2.5.4 Expansion & Sub-Culture
10.2.6 Historic and Forecasted Market Size By Treatment Type
10.2.6.1 Allogeneic Stem Cell Therapy
10.2.6.2 Auto Logic Stem Cell Therapy
10.2.6.3 Syngeneic Stem Cell Therapy
10.2.7 Historic and Forecasted Market Size By Application
10.2.7.1 Neurological Disorders
10.2.7.2 Orthopedic Treatments
10.2.7.3 Oncology Disorders
10.2.7.4 Injuries & Wounds
10.2.7.5 Drug Discovery & Development
10.2.7.6 and Other
10.2.8 Historic and Forecasted Market Size By End-User
10.2.8.1 Pharmaceutical and Biotechnology Companies
10.2.8.2 Hospitals & Cell Banks
10.2.8.3 Academic & Research Institutes
10.2.9 Historic and Forecast Market Size by Country
10.2.9.1 US
10.2.9.2 Canada
10.2.9.3 Mexico
10.3 . Eastern Europe Stem Cell Market
10.3.1 Key Market Trends, Growth Factors and Opportunities
10.3.2 Top Key Companies
10.3.3 Historic and Forecasted Market Size by Segments
10.3.4 Historic and Forecasted Market Size By Product Type
10.3.4.1 Adult Stem Cells (ASCs)
10.3.4.2 Human Embryonic Stem Cells (HESCs)
10.3.4.3 Induced Pluripotent Stem Cells (iPSCs)
10.3.4.4 Very Small Embryonic Like Stem Cells
10.3.5 Historic and Forecasted Market Size By Technology
10.3.5.1 Cell Acquisition
10.3.5.2 Cell Production
10.3.5.3 Cryopreservation
10.3.5.4 Expansion & Sub-Culture
10.3.6 Historic and Forecasted Market Size By Treatment Type
10.3.6.1 Allogeneic Stem Cell Therapy
10.3.6.2 Auto Logic Stem Cell Therapy
10.3.6.3 Syngeneic Stem Cell Therapy
10.3.7 Historic and Forecasted Market Size By Application
10.3.7.1 Neurological Disorders
10.3.7.2 Orthopedic Treatments
10.3.7.3 Oncology Disorders
10.3.7.4 Injuries & Wounds
10.3.7.5 Drug Discovery & Development
10.3.7.6 and Other
10.3.8 Historic and Forecasted Market Size By End-User
10.3.8.1 Pharmaceutical and Biotechnology Companies
10.3.8.2 Hospitals & Cell Banks
10.3.8.3 Academic & Research Institutes
10.3.9 Historic and Forecast Market Size by Country
10.3.9.1 Russia
10.3.9.2 Bulgaria
10.3.9.3 The Czech Republic
10.3.9.4 Hungary
10.3.9.5 Poland
10.3.9.6 Romania
10.3.9.7 Rest of Eastern Europe
10.4 . Western Europe Stem Cell Market
10.4.1 Key Market Trends, Growth Factors and Opportunities
10.4.2 Top Key Companies
10.4.3 Historic and Forecasted Market Size by Segments
10.4.4 Historic and Forecasted Market Size By Product Type
10.4.4.1 Adult Stem Cells (ASCs)
10.4.4.2 Human Embryonic Stem Cells (HESCs)
10.4.4.3 Induced Pluripotent Stem Cells (iPSCs)
10.4.4.4 Very Small Embryonic Like Stem Cells
10.4.5 Historic and Forecasted Market Size By Technology
10.4.5.1 Cell Acquisition
10.4.5.2 Cell Production
10.4.5.3 Cryopreservation
10.4.5.4 Expansion & Sub-Culture
10.4.6 Historic and Forecasted Market Size By Treatment Type
10.4.6.1 Allogeneic Stem Cell Therapy
10.4.6.2 Auto Logic Stem Cell Therapy
10.4.6.3 Syngeneic Stem Cell Therapy
10.4.7 Historic and Forecasted Market Size By Application
10.4.7.1 Neurological Disorders
10.4.7.2 Orthopedic Treatments
10.4.7.3 Oncology Disorders
10.4.7.4 Injuries & Wounds
10.4.7.5 Drug Discovery & Development
10.4.7.6 and Other
10.4.8 Historic and Forecasted Market Size By End-User
10.4.8.1 Pharmaceutical and Biotechnology Companies
10.4.8.2 Hospitals & Cell Banks
10.4.8.3 Academic & Research Institutes
10.4.9 Historic and Forecast Market Size by Country
10.4.9.1 Germany
10.4.9.2 UK
10.4.9.3 France
10.4.9.4 The Netherlands
10.4.9.5 Italy
10.4.9.6 Spain
10.4.9.7 Rest of Western Europe
10.5 . Asia Pacific Stem Cell Market
10.5.1 Key Market Trends, Growth Factors and Opportunities
10.5.2 Top Key Companies
10.5.3 Historic and Forecasted Market Size by Segments
10.5.4 Historic and Forecasted Market Size By Product Type
10.5.4.1 Adult Stem Cells (ASCs)
10.5.4.2 Human Embryonic Stem Cells (HESCs)
10.5.4.3 Induced Pluripotent Stem Cells (iPSCs)
10.5.4.4 Very Small Embryonic Like Stem Cells
10.5.5 Historic and Forecasted Market Size By Technology
10.5.5.1 Cell Acquisition
10.5.5.2 Cell Production
10.5.5.3 Cryopreservation
10.5.5.4 Expansion & Sub-Culture
10.5.6 Historic and Forecasted Market Size By Treatment Type
10.5.6.1 Allogeneic Stem Cell Therapy
10.5.6.2 Auto Logic Stem Cell Therapy
10.5.6.3 Syngeneic Stem Cell Therapy
10.5.7 Historic and Forecasted Market Size By Application
10.5.7.1 Neurological Disorders
10.5.7.2 Orthopedic Treatments
10.5.7.3 Oncology Disorders
10.5.7.4 Injuries & Wounds
10.5.7.5 Drug Discovery & Development
10.5.7.6 and Other
10.5.8 Historic and Forecasted Market Size By End-User
10.5.8.1 Pharmaceutical and Biotechnology Companies
10.5.8.2 Hospitals & Cell Banks
10.5.8.3 Academic & Research Institutes
10.5.9 Historic and Forecast Market Size by Country
10.5.9.1 China
10.5.9.2 India
10.5.9.3 Japan
10.5.9.4 South Korea
10.5.9.5 Malaysia
10.5.9.6 Thailand
10.5.9.7 Vietnam
10.5.9.8 The Philippines
10.5.9.9 Australia
10.5.9.10 New Zealand
10.5.9.11 Rest of APAC
10.6 . Middle East & Africa Stem Cell Market
10.6.1 Key Market Trends, Growth Factors and Opportunities
10.6.2 Top Key Companies
10.6.3 Historic and Forecasted Market Size by Segments
10.6.4 Historic and Forecasted Market Size By Product Type
10.6.4.1 Adult Stem Cells (ASCs)
10.6.4.2 Human Embryonic Stem Cells (HESCs)
10.6.4.3 Induced Pluripotent Stem Cells (iPSCs)
10.6.4.4 Very Small Embryonic Like Stem Cells
10.6.5 Historic and Forecasted Market Size By Technology
10.6.5.1 Cell Acquisition
10.6.5.2 Cell Production
10.6.5.3 Cryopreservation
10.6.5.4 Expansion & Sub-Culture
10.6.6 Historic and Forecasted Market Size By Treatment Type
10.6.6.1 Allogeneic Stem Cell Therapy
10.6.6.2 Auto Logic Stem Cell Therapy
10.6.6.3 Syngeneic Stem Cell Therapy
10.6.7 Historic and Forecasted Market Size By Application
10.6.7.1 Neurological Disorders
10.6.7.2 Orthopedic Treatments
10.6.7.3 Oncology Disorders
10.6.7.4 Injuries & Wounds
10.6.7.5 Drug Discovery & Development
10.6.7.6 and Other
10.6.8 Historic and Forecasted Market Size By End-User
10.6.8.1 Pharmaceutical and Biotechnology Companies
10.6.8.2 Hospitals & Cell Banks
10.6.8.3 Academic & Research Institutes
10.6.9 Historic and Forecast Market Size by Country
10.6.9.1 Turkiye
10.6.9.2 Bahrain
10.6.9.3 Kuwait
10.6.9.4 Saudi Arabia
10.6.9.5 Qatar
10.6.9.6 UAE
10.6.9.7 Israel
10.6.9.8 South Africa
10.7 . South America Stem Cell Market
10.7.1 Key Market Trends, Growth Factors and Opportunities
10.7.2 Top Key Companies
10.7.3 Historic and Forecasted Market Size by Segments
10.7.4 Historic and Forecasted Market Size By Product Type
10.7.4.1 Adult Stem Cells (ASCs)
10.7.4.2 Human Embryonic Stem Cells (HESCs)
10.7.4.3 Induced Pluripotent Stem Cells (iPSCs)
10.7.4.4 Very Small Embryonic Like Stem Cells
10.7.5 Historic and Forecasted Market Size By Technology
10.7.5.1 Cell Acquisition
10.7.5.2 Cell Production
10.7.5.3 Cryopreservation
10.7.5.4 Expansion & Sub-Culture
10.7.6 Historic and Forecasted Market Size By Treatment Type
10.7.6.1 Allogeneic Stem Cell Therapy
10.7.6.2 Auto Logic Stem Cell Therapy
10.7.6.3 Syngeneic Stem Cell Therapy
10.7.7 Historic and Forecasted Market Size By Application
10.7.7.1 Neurological Disorders
10.7.7.2 Orthopedic Treatments
10.7.7.3 Oncology Disorders
10.7.7.4 Injuries & Wounds
10.7.7.5 Drug Discovery & Development
10.7.7.6 and Other
10.7.8 Historic and Forecasted Market Size By End-User
10.7.8.1 Pharmaceutical and Biotechnology Companies
10.7.8.2 Hospitals & Cell Banks
10.7.8.3 Academic & Research Institutes
10.7.9 Historic and Forecast Market Size by Country
10.7.9.1 Brazil
10.7.9.2 Argentina
10.7.9.3 Rest of SA
Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies
Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research
|
Global Stem Cell Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 12.94 Bn. |
|
Forecast Period 2024-32 CAGR: |
7.4% |
Market Size in 2032: |
USD 24.60 Bn. |
|
Segments Covered: |
By Product Type |
|
|
|
By Technology |
|
||
|
By Treatment Type |
|
||
|
By Application
|
|
||
|
By End-User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Stem Cell Market research report is 2024-2032.
Aspen Neuroscience (USA), Thermo Fisher Scientific (USA), Kite Pharma (Gilead Sciences) (USA), Stemcell Technologies (Canada), Lonza Group (Switzerland), Bluebird Bio (USA), Organovo (USA), Astellas Pharma (Japan), Cynata Therapeutics (Australia), Celgene (Bristol-Myers Squibb) (USA), Novartis (Switzerland), Regeneron Pharmaceuticals (USA), Sangamo Therapeutics (USA), Regenexx (USA), Stemline Therapeutics (Astellas Pharma) (USA), Tigenix (Takeda Pharmaceutical) (Belgium), NuVasive (USA), International Stem Cell Corporation (USA), AlloVir (USA), Fate Therapeutics (USA), Mesoblast Limited (Australia), and Other Active Players.
The Stem Cell Market is segmented into By Product Type, Technology, Application, Treatment Type, End-User, and Region. By Product Type, the market is categorized into Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs), Very Small Embryonic Like Stem Cells. Technology, the market is categorized into Cell Acquisition, Cell Production, Cryopreservation, Expansion & Sub-Culture. Application the market is categorized into Cell Acquisition, Cell Production, Cryopreservation, Expansion & Sub-Culture. Treatment Type The market is categorized into Allogeneic Stem Cell Therapy, Auto Logic Stem Cell Therapy, and Syngeneic Stem Cell Therapy. By End-User the market is categorized in Pharmaceutical and Biotechnology Companies, Hospitals & Cell Banks, Academic & Research. Institutes. By region it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Russia; Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Stem cells are cells with the ability to develop into many different types of cells in the body. They provide a repair system for the body. There are two main types of stem cells: adult stem cells and embryonic stem cells. Stem cells are found in almost all tissues of the body. They are needed for the maintenance of tissue and also for repair after injury.
Stem Cell Market Size Was Valued at USD 12.94 Billion in 2023 and is Projected to Reach USD 24.60 Billion by 2032, Growing at a CAGR of 7.4% From 2024-2032.
